Latest HLA-B Stories
The International Serious Adverse Events Consortium (SAEC) announced today initial results from its research designed to discover genetic markers that may predict individuals at risk for serious drug induced liver injury (DILI).
People with the ability to stave off AIDS for years after initial infection by HIV have been called "long-term non-progressors" or "elite controllers."
Mutations that help HIV hide from the immune system undermine the virus's ability to replicate, show an international team of researchers in the April 13 issue of the Journal of Experimental Medicine.
DEAR DR. DONOHUE: My brother was recently told he has ankylosing spondylitis. He's in his early 50s and has posture like Ed Sullivan, who had the same disease. He gives himself a shot of Humira. He has a lot of pain.
LinkMeds wholly owned subsidiary Olerup SSP has developed a new test that detects genetic variations in the human leucocyte antigen system that indicates risk for severe adverse reactions to Abacavir in HIV patients. The test is marketed and sold by Qiagen.
HLA-B*5701 biomarker indicates risk for severe adverse reactions to Abacavir / Experts expect more tests for similar markers in the future Venlo, The Netherlands - August 19, 2008 - QIAGEN (Nasdaq: QGEN; Frankfurt Prime Standard: QIA) today announced that it has introduced a new molecular diagnostic test to type the HLA-B*5701 allele, a genetic variation in the Human Leucocyte Antigen (HLA) system.
Researchers at University of Cape Town in South Africa reported Friday the discovery of a variation of an immunity gene that weakens the human immunodeficiency virus (HIV), slowing down the progression of AIDS and making the virus less potent if transmitted to others.